Original Publication Date: 1 July, 2014
Publication / Source: Biomarkers in Medicine
Authors: Gemma Cramarossa, Esther K Lee, Lavarnan Sivanathan et al
Low-dose metronomic (LDM) chemotherapy is a beneficial and very well-tolerated form of chemotherapy utilization characterized by the frequent and uninterrupted administration of low doses of conventional chemotherapeutic agents over prolonged periods of time. While patients resistant to standard maximum tolerated dose (MTD) chemotherapy may still benefit from LDM chemotherapy, there is a lack of predictive markers of response to LDM chemotherapy.
To view restricted content, please:
